Clinical trial
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent…
NCT00471432 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00471432 |
|---|---|
| Title | OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors |
| Official title | A Phase I Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination With Docetaxel |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Bladder Cancer, Breast Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | custirsen sodium, docetaxel, pharmacological study |
| Enrollment | 40 |
| Start date | Apr 4, 2003 |
| Primary completion | Mar 9, 2006 |
| Completion | Dec 21, 2009 |
| First posted | May 10, 2007 |
| Last update posted | Aug 4, 2023 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: